INIS
patients
100%
drugs
93%
evaluation
53%
hospitals
43%
therapy
34%
pharmacology
26%
control
19%
reviews
18%
assessments
18%
insulin
16%
safety
16%
density
14%
biopsy
13%
injuries
13%
pediatrics
13%
pregnancy
13%
prostate
13%
rectum
13%
intake
13%
interactions
13%
validation
13%
reliability
13%
attitudes
13%
screening
13%
standardization
13%
surveys
13%
nutrition
13%
viruses
13%
diabetes mellitus
13%
lipoproteins
13%
learning
13%
liver
13%
cancer
13%
humans
13%
connections
13%
interleukins
13%
rats
13%
heart failure
13%
doses
12%
diseases
12%
tools
11%
cholesterol
10%
levels
9%
hiv
8%
angiotensin
8%
blood
8%
comparative evaluations
7%
females
7%
receptors
6%
monoclonal antibodies
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
23%
Adverse Drug Reaction
17%
Drug
17%
Opportunistic Infection
13%
Oral Antidiabetic Agent
13%
Valsartan/Sacubitril
13%
Familial Hypercholesterolemia
13%
Liver Injury
13%
Wistar Rat
13%
Insulin
13%
Modafinil
13%
Toxic Hepatitis
11%
Lactic Acidosis
6%
Headache
6%
Zidovudine
6%
Nevirapine
6%
Efavirenz
6%
Stavudine
6%
Peripheral Neuropathy
6%
Rash
6%
Anemia
6%
Pancreatitis
6%
Human Immunodeficiency Virus Infection
5%
Hepatotoxicity
5%
Ensure
5%
Adverse Event
5%
Diabetes Mellitus
5%
Medicine and Dentistry
Hospital
17%
Drug Therapy
14%
Patient
13%
Maturity Onset Diabetes of the Young
13%
Geriatrics
13%
Pediatrics
13%
Digital Rectal Examination
13%
Screening
13%
Prostate Biopsy
13%
Antidiabetic Agent
13%
Prostate Cancer
13%
Discharge
13%
Age Groups
9%
Inpatient
6%
Hemoglobin A1c
5%